Investigational drug · Phase 2
PBSS1113
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Acute Myeloid Leukemia (AML), MDS (Myelodysplastic Syndrome).
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "PBSS1113"
First trial start
2025
Sep 8, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PBSS1113", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acute Myeloid Leukemia (AML)
- MDS (Myelodysplastic Syndrome)
Approved drugs for the same conditions: Acute myeloid leukemia · Myelodysplastic syndromes · Hematology and blood cancers · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "PBSS1113" as an intervention, largest first.
Chaser Therapeutics, Inc.Industry
NCT07761533 · 29 participants (planned) · Start Sep 8, 2025 · Primary completion Sep 2027
Drug: PBSS1113 · For: Acute Myeloid Leukemia (AML); MDS (Myelodysplastic Syndrome)
Sites: Hangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Acute Myeloid Leukemia (AML)
- BP1001Phase 21 trial
Bio-Path Holdings, Inc. · Acute Myeloid Leukemia (AML)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.